Leukotrienes (LTs) are mediators of inflammation (1) formed by immune cells in response to pathogens or danger signals. When cells are stimulated, cytosolic phospholipase A 2 (cPLA 2 ) and 5-lipoxygenase (LO) migrate to the nuclear membrane, arachidonic acid (AA) is released from nuclear membrane phospholipids, and LTA 4 is produced (2). Efficient translocation and activation of 5-LO requires two scaffold proteins, 5-LO activating protein (FLAP) and coactosin-like protein (CLP) (3). LTA 4 is then further metabolized by cytosolic LTA 4 hydrolase to LTB 4 , or by LTC 4 synthase (LTC 4 S) to LTC 4 . LTC 4 S is primarily located at the nuclear membrane together with FLAP, and both proteins are members of the family of membrane bound proteins involved in eicosanoid and glutathione metabolism (MAPEG). LTC 4 and its metabolites, LTD 4 and LTE 4 , are jointly referred to as the cysteinyl LTs (CysLTs). CysLTs elicit edema formation, mucus secretion, and smooth muscle contraction, as well as eosinophil trafficking and tissue remodeling, and thus contribute to symptoms in several chronic inflammatory diseases, such as asthma (4). There are at least three different receptors for the CysLTs; in the lung, bronchoconstriction and other effects are mediated via CysLT1. LTD 4 has a 10-to 50-fold higher potency for activation of CysLT1 compared with LTC 4 , while LTE 4 is the least active (5, 6). Thus, metabolism of LTC 4 to LTD 4 may have a considerable impact on CysLT1-mediated effects, also depending on further conversion to LTE 4 .
Abstract Leukotrienes (LTs